Research advances of rituximab resistance in B-cell non-Hodgkin lymphoma
10.3760/cma.j.issn.1009-9921.2013.05.020
- VernacularTitle:利妥昔单抗治疗B细胞非霍奇金淋巴瘤的耐药机制研究进展
- Author:
Jianqiu WU
- Publication Type:Journal Article
- Keywords:
Lymphoma,non-Hodgkin;
Monoclonal antibody;
Immunity;
Drug resistance
- From:
Journal of Leukemia & Lymphoma
2013;22(5):312-314
- CountryChina
- Language:Chinese
-
Abstract:
Anti-CD20 monoclonal antibody rituximab has become an essential component of treatment regimens for B-cell non-Hodgkin lymphoma(NHL).It is routinely incorporated into all phases of conventional treatment of B-cell NHL,but the precise mechanisms of action of rituximab in human remain unknown.This article will clarify the mechanisms of action of rituximab,the incidence and potential mechanisms of resistance.Finally,the novel approaches to modulate the antibody,the tumor cell,and the host immunologic environment to overcome rituximab resistance are discussed.
